Eosinophilic Esophagitis and Non-GERD Esophagitis

Published on 27/03/2015 by admin

Filed under Pediatrics

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1424 times

Chapter 316 Eosinophilic Esophagitis and Non-GERD Esophagitis

Eosinophilic Esophagitis

The esophageal epithelium in eosinophilic esophagitis (EoE) is infiltrated by eosinophils, typically in a density exceeding 15 per high-power field (hpf). Presenting symptoms include vomiting, feeding problems, chest or epigastric pain, and dysphagia with occasional food impactions or strictures. Most patients are male. The mean age at diagnosis is 7 yr (range 1-17 yr), and the duration of symptoms is 3 yr. Most patients have other atopic diseases and associated food allergies; laboratory abnormalities can include peripheral eosinophilia and elevated immunoglobulin E (IgE) levels. Endoscopically, the esophagus presents a granular, furrowed, ringed, or exudative appearance (Fig. 316-1); esophageal histology reveals eosinophilia, with cut-points for diagnosis variably chosen at 15-20/hpf. Up to 30% children with EoE have grossly normal esophageal mucosa. EoE is differentiated from gastroesophageal reflux disease (GERD) by its general lack of erosive esophagitis, by its greater eosinophil density, and by its refractoriness to antireflux therapies. Gastroesophageal reflux disease may be an important coexisting diagnosis. Evaluation of EoE should include a thorough search for food and environmental allergies via skin prick (IgE mediated) and patch (non–IgE mediated) tests.

Treatment involves dietary restrictions that take one of 3 forms: elimination diets guided by circumstantial evidence and food allergy test results; “six food elimination diet” removing the major food allergens (milk, soy, wheat, egg, peanuts and tree nuts, seafood); and elemental diet composed exclusively of an amino acid–based formula. Successful clinical and histologic remission is observed in 70-98% patients. Topical and systemic corticosteroids have been used successfully for nonresponders and for nonallergic (“primary”) EoE, with symptomatic and histologic remission rates reaching 90%. Therapies under investigation include anti–interleukin 5 (anti-IL-5) antibody (mepolizumab, reslizumab). Little is yet known about its natural history, but it seems that EoE is a chronic remitting and relapsing disorder with a potential for complications such as stricture formation.